Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Past 24 hours
Any time
Past hour
Past 7 days
Past 30 days
Most recent
Best match
26m
What's Next For Johnson & Johnson Stock?
Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.
BioSpace
22h
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...
22h
on MSN
Johnson & Johnson (NYSE:JNJ) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
One Direction singer dies
Fox News interview
NH justice indicted
Exotic cat caught in suburb
Felon voting rights upheld
Italy expands surrogacy ban
Gets minimum 28 years
Disney to debut new pass
To return to Atlanta in 2028
FDA halts Novavax trial
Had benign cyst removed
Abortion group sues Florida
AL voter roll purge blocked
'Click to cancel' finalized
MI shooter drill settlement
21K+ SUVs recalled
Allows EPA emissions rule
Synthetic nicotine pouches
To settle US bribery probe
SpaceX sues CA regulators
Cereal dyes protested
New cervical cancer regimen
To headline Atlanta rally
GA election rules blocked
Ordered to pay $15 million
To invest in nuclear reactors
Sentenced for cartel bribery
To cut up to 2,500 jobs
Related topics
Ustekinumab
United States
Eli Lilly and Company
Johnson & Johnson
Crohn's disease
Feedback